Wall Street brokerages predict that Amedisys Inc (NASDAQ:AMED) will report $394.96 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Amedisys’ earnings, with estimates ranging from $390.40 million to $400.46 million. Amedisys reported sales of $366.30 million during the same quarter last year, which would suggest a positive year over year growth rate of 7.8%. The firm is expected to report its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Amedisys will report full year sales of $394.96 million for the current fiscal year. For the next year, analysts expect that the company will post sales of $1.63 billion per share, with estimates ranging from $1.60 billion to $1.66 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Amedisys.
Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Amedisys from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 7th. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Mizuho reiterated a “buy” rating and issued a $65.00 target price (up previously from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Benchmark reiterated a “hold” rating on shares of Amedisys in a research note on Thursday, November 9th. Finally, Craig Hallum restated a “buy” rating and set a $68.00 price objective (up previously from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $60.64.
Amedisys (NASDAQ AMED) opened at $56.40 on Monday. The stock has a market cap of $1,914.03, a P/E ratio of 26.99, a PEG ratio of 1.18 and a beta of 0.73. Amedisys has a 52 week low of $45.60 and a 52 week high of $65.91. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.